Characteristics
|
N
|
Malaria prevalence n (%)
|
P-value
|
AOR
|
95% CI
|
P-value
|
---|
WHO clinical stage
| | | | | | |
Stage I
|
338
|
12 (3.6)
| |
1
| | |
Stage II
|
43
|
2 (4.7)
| |
0.851
|
0.171-4.226
|
0.844
|
Stage III-IV
|
39
|
5 (12.8)
|
0.031a
|
2.305
|
0.699-7.597
|
0.170
|
CD4 count (cells/μL)*
| | | | | | |
≥500
|
104
|
4 (3.8)
| |
-
| | |
350-499
|
85
|
3 (3.5)
| |
-
| | |
200-349
|
96
|
8 (8.3)
| |
−
| | |
<200
|
59
|
4 (6.8)
|
0.417a
|
-
| | |
Pregnancy trimester
| | | | | | |
1st trimester
|
20
|
1 (5)
| |
-
| | |
2nd trimester
|
206
|
9 (4.4)
| |
-
| | |
3rd trimester
|
194
|
9 (4.6)
|
0.986a
|
-
| | |
Gravidity
| | | | | | |
Primigravidae
|
139
|
6 (4.3)
| |
-
| | |
Secundigravidae
|
148
|
5 (3.4)
| |
-
| | |
Multigravidae
|
133
|
8 (6)
|
0.563a
|
-
| | |
Adherence to co-trimoxazole
| | | | | | |
Good
|
208
|
2 (1)
| |
1
| | |
Average
|
80
|
4 (5)
| |
3.578
|
0.611-20.955
|
0.157
|
Poor
|
132
|
13 (9.8)
|
0.001a
|
6.806
|
1.346-34.429
|
0.02
|
ITN use
| | | | | | |
Yes
|
380
|
15 (3.9)
| |
-
| | |
No
|
40
|
4 (10)
|
0.096b
|
-
| | |
ART use category
| | | | | | |
Prophylaxis
|
288
|
11 (3.8)
| |
-
| | |
Life long
|
132
|
8 (6.1)
|
0.305a
|
-
| | |
-
aCalculated by Pearson Chi Square, bCalculated by Fischer’s Exact Test, *Results of CD4 count were available for only 344 subjects out of 420 (81.9%).